GAITHERSBURG, Md., Aug. 14 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it has promoted Edward T. Mathers to
executive vice president, corporate development and venture. In this role, he
is responsible for the company's licensing and business development activities
and is a key leader of the company's MedImmune Ventures, Inc. team evaluating
"Since joining MedImmune in 2002, Ed has been an instrumental part of
implementing our long-term plan to build one of the best product portfolios in
the industry," said David M. Mott, chief executive officer and president.
"Ed's work in expanding our pipeline through in-licensing and acquisition
opportunities has complemented our increased investment in internally driven
research and development. During the past 18 months alone, Ed and his team
have successfully completed 16 strategic transactions, including in-
licensings, collaborations and a company acquisition. In the same timeframe,
our ventures team, which he helps lead, has completed 14 strategic investments
in promising young companies that have the potential to bring meaningful
financial and scientific rewards to MedImmune in the future. Ed is also a key
member of our executive management team, critically involved in strategic
direction and operations of the company.
"I look forward to continuing to work with Ed and his team as we strive to
achieve our long-term goals to become one of the most productive and
profitable biotech companies in the industry while contributing meaningfully
to the advancement of human health," Mott concluded.
Prior to joining MedImmune, Mr. Mathers was vice president of marketing
and corporate licensing and acquisitions at Inhale Therapeutic Systems.
Previously, he enjoyed a successful 15-year career at Glaxo Wellcome, Inc.,
holding a number of increasingly responsible positions in sales and marketing.
Mr. Mathers began his career as a researcher at Ortho Pharmaceuticals
Corporation, a division of Johnson & Johnson. Mr. Mathers holds a bachelor's
degree in chemistry from North Carolina State University.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,300 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
This announcement contains, in addition to historical information, certain
"forward-looking statements" regarding MedImmune's long-term, strategic
objectives. Such forward-looking statements are based on current expectations
and involve inherent risks and uncertainties, including factors that could
delay, divert or change current expectations and could cause actual outcomes
and results to differ materially from current expectations. In addition to
risks and uncertainties discussed in MedImmune's filings with the U.S.
Securities and Exchange Commission, no assurance exists that development
efforts for the company's pipeline programs will succeed, that these programs
will receive required regulatory approval or that, even if regulatory approval
is received, products resulting from these programs will be commercially
successful. MedImmune undertakes no obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise
except as may be required by applicable law or regulation.
SOURCE MedImmune, Inc.
CONTACT: Media: Jamie Lacey, +1-301-398-4035 or Clarencia Stephen,
+1-301-398-4073; or Investors: Peter Vozzo, +1-301-398-4358 or Beatrice
Pierre, +1-301-398-4905, all of MedImmune, Inc.